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Available online 21 October 2016Objective:HTLV-1-associatedmyelopathy/tropical spastic paraparesis (HAM/TSP) can progress slowly or rapidly
even though a set of symptoms such as spastic paraparesis with pathological reﬂexes and sweating loss of the
lower extremities are commonly observed in patients. Although most of the patients are thought to be infected
to HTLV-1 from theirmothers by breast feeding, symptoms of HAM/TSP typicallymanifest in patients later in life
(50–60 years old in age) and also with a higher prevalence of women to men at a ratio of approximately 3:1.
Probability of developing HAM/TSP and how fast an individual's disease may progress from the time of diagnosis
could be multifactorial.
Methods:We reviewed the records of 150 patientswith HAM/TSP admitted to KagoshimaUniversity Hospital be-
tween 2002 and 2014. Laboratory data of cerebrospinal ﬂuid and serum and the clinicalmeasurements including
age, age of disease onset, progression rate, duration of illness, initial symptoms, Osame's Motor Disability Score
were evaluated. Rapid disease progression of the disease was deﬁned by deterioration of motor disability by
N3 grades within 2 years.
Results:Of 150HAM/TSP patients in our cohort, 114 cases (76%)were females. Patients presentingwith rapid dis-
ease progression are approximately 15 years older at the age of onset than thosewith a protracteddisease course,
and have increased number of cell, and elevated levels of protein aswell as anti-HTLV-1 antibody titer in the CSF,
suggesting a more active inﬂammatory process. There is no signiﬁcant difference in the average values of clinical
and laboratory parameters between the sexes. Furthermore, there is no apparent correlation between rate of dis-
ease progression and gender.
Conclusions: Our results suggest that age and virus mediated inﬂammation are correlated with disease pheno-
types while additional factors such as host or HTLV-1 genetics and gender may inﬂuence disease susceptibility.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
HAM/TSP
Disease course
Rapid progression
Gender1. Introduction
Human T-lymphotropic virus type 1 (HTLV-1) is the ﬁrst human on-
cogenic retrovirus to be identiﬁed and is thought to infect at least 50
million people worldwide [1,2]. Several endemic areas for HTLV-1 are
known in the world such as southern Japan, the Caribbean, Centraldeclare. Authors' contribution:
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the ﬁnal version of this paper.
gy and Geriatrics, Kagoshima
ciences, 8-35-1 Sakuragaoka,
atsuura).
. This is an open access article underand South America, Middle East, Central and West Africa, Melanesia,
and there are smaller foci in the aboriginal populations of Australia,
Papua New Guinea, and northern Japan [3–5]. HTLV-1 can be transmit-
ted through breastfeeding from mother to child, blood transfusion, and
sexual intercourse. The majority of infected individuals remain lifelong
asymptomatic carriers, and approximately 2–5% develop adult T-cell
leukemia/lymphoma (ATLL) [6,7] and another 0.25–3.8% develop
HTLV-1-associatedmyelopathy/tropical spastic paraparesis (HAM/TSP).
Disease phenotypes of HAM/TSP can be heterogeneous even
though a set of symptoms such as spastic paraparesis with patholog-
ical reﬂexes, urinary disturbance, mild sensory disturbance and
sweating loss of the lower extremities are commonly observed in pa-
tients. Based on longitudinal clinical observations and follow-ups,
HAM/TSP can be characterized as rapidly or slowly progressive
types. Approximately 30% of HAM/TSP patients exhibit rapidthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Distribution of ages at disease onset.
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ability to walk is b2 years. Contrasting the rapid disease phenotype is
the slow, protracted form of disease which can take as long as
15 years to progress [8]. Factors that may inﬂuence how fast an
individual's disease may progress are yet to be identiﬁed, while sev-
eral risk factors including HTLV-1 provirus load (PVL), HTLV-1 sub-
type, human leukocyte antigen (HLA) and non-HLA gene
polymorphisms are closely associated with the development of
HAM/TSP [9]. The major route of HTLV-1 infection is from mothers
by a breastfeeding. Symptoms of HAM/TSP, however, typically man-
ifest in patients later in life (50–60 years old in age) and also with a
higher prevalence of women to men at a ratio of approximately 3:1
[8,10–12]. The reasons for these characteristics of this unique infec-
tious disease also remain unknown. A complex multi-step pathogen-
ic process leading to disease manifestation may in part explain the
long latency in disease development. Nevertheless, few studies
have to-date attempted to address the elevated female prevalence
in HAM/TSP.
We designed a retrospective comparative study of 150 sequential
patients admitted to our hospital in the last 12 years and tried to
identify disease determinants or biomarkers that may be of value
to clinicians when assessing HTLV-1 related disease subtypes.
2. Subjects and methods
We reviewed the medical records of 150 consecutive patients
with HAM/TSPwhowere admitted to Kagoshima University Hospital
from January 2002 to June 2014. HAM/TSP was diagnosed according
to theWorld Health Organization diagnostic criteria [13]. Clinical in-
formation was obtained from medical records of patient attendance
at our hospital. Clinical variables included sex, age, age at onset, an
initial symptom, a score of a neurological disability and blood and ce-
rebrospinal ﬂuid (CSF) tests. Neurological disability was assessed
using Osame's Motor Disability Score (OMDS) as reported previous-
ly. The score were deﬁned as follows: 0, no disability; 1, walking
slow; 2, a little trouble when walking; 3, unable to run; 4, needs
guardrail while going up the stairs; 5, needs one hand support
while walking; 6, needs two hands support while walking (N10 m);
and 7, needs two hands support while walking (b10 m); 8, needs
two hands support while walking (b5 m); 9, unable to walk but
can crawl; 10, unable to crawl but can move; 11, unable to move
but can roll over on the bed; 12 unable to roll over; 13, unable to
ﬂex toes [14].
The subgroup of the patients with rapid progression was deﬁned
by deterioration of motor disability by N3 grades within 2 years. This
deﬁnition was applied to disease onset and any time point in the dis-
ease course. A routine test for blood and cerebrospinal ﬂuid of the
patients were evaluated. Anti-HTLV-1 antibodies in serum and CSF
were detected using enzyme-linked immunosorbent assay and par-
ticle agglutination methods (Fijirebio Inc., Tokyo, Japan). HTLV-1
PVL in peripheral blood mononuclear cells (PBMCs) was assayed by
quantitative PCR using the ABI PRISM 7700TM sequence detection
system as reported previously [15]. We analyzed these laboratory
data and the clinical parameters including the sex, age of disease
onset, initial symptom and disease course.
HTLV-1 PVL of asymptomatic carriers was measured with the blood
samples from 89 individuals after obtaining informed consent.
2.1. Statistical analysis
Data were analyzed using SPSS-20 (SPSS, Chicago, Illinois).
Statistical analyses were performed using parametric (t-test) and
non-parametric tests (Mann–Whitney test) for continuous variables
and χ2 (Pearson χ2 test/Fisher exact test) for categorical variables.
Differences were considered signiﬁcant when p b 0.05.3. Results
3.1. Clinical and laboratory data of the patients with HAM/TSP
Wemade a bar chart representing a frequency distribution of age of
disease onset with 150 consequent patients who had been diagnosed
with HAM/TSP from 2002 and 2014. The probability of developing
symptoms at any given age was in accordance with a skewed normal
distribution pattern (Fig. 1). Between the 5th and 7th decades, was
when the chances of developing HAM/TSP disease increase. The aver-
ages of age, age of onset, and duration of illness of all the patients
were 61.5 years old, 50.6 years old and 10.9 years, respectively (Table
1). On the laboratory data, the average of anti-HTLV-1 antibody titer
(PA) in serum and cerebral spinal ﬂuid (CSF) of all the patients were
29,141× and 594.2×, respectively. Average of HTLV-1 proviral load
(PVL)was 9.42% in PBMCs. There is no signiﬁcant difference in these pa-
rameters other than the level of protein in the CSF between the sexes.
The level of protein in the CSF of the female patients was signiﬁcantly
less than that of the male patients, while there is no difference in a
cell count and a level of neopterin between them (Table 1).
3.2. Characteristics of the patients presenting with rapid and slow disease
progression
We segregated patients into two groups based on disease pheno-
types, and compared the groups (Table 2). The patients presenting
with rapid progression were signiﬁcantly older at onset than those
with slow progression (61.5 vs. 46.8 years old, p b 0.001). The time
elapse between onset and wheelchair use in daily life was markedly
shorter among patients with rapidly progressing disease (1.4 vs.
15.7 years, p b 0.001). Anti-HTLV-1 antibody titer was also signiﬁcantly
higher in the CSF of the patientswith rapid progression than in thatwith
slow progression (1210× vs. 366×, p b 0.001), but the difference in the
titer was not found in the serum. Cell counts and the protein level were
signiﬁcantly higher in the CSF of the patients with rapid progression
than in that with slow progression (11.1 vs. 3.3 cells, p b 0.001; 54.9
vs. 36.1 mg/dl, p b 0.001, respectively). HTLV-1 PVL was signiﬁcantly
lower in patients with rapid progression than in those with slow pro-
gression (408 vs. 1158 copies/104 PBMCs, p=0.008). The PVL of the pa-
tients with rapid progression was slightly higher than that with
asymptomatic carriers in our hospital is 366 ± 657 copies.
Wewondered if initial presentationswere prognostic, and tabulated
frequencies of ﬁve common symptoms including gait disturbance, uri-
nary and sensory disturbances, constipation and lumbago (Fig. 2). Pa-
tients were separated into cohorts based on their respective divergent
disease courses for further analysis (Fig. 2a). Our result, albeit sugges-
tive, demonstrates that urinary disorders were more often noticed in
Table 1
HAM/TSP clinical and laboratory parameters between male and female.
Number of patients All (N = 150) Male (N = 36) Female (N = 114) p
Age (mean ± s.d., range) 61.5 ± 12.2 (N = 151) 62.7 ± 11.8 (N = 36) 61.1 ± 12.3 (N = 114) NS
Age of onset (mean ± s.d., range) 50.6 ± 15.7 (N = 151) 52.8 ± 14.1 (N = 36) 49.9 ± 16.1 (N = 114) NS
Duration of illness (mean ± s.d., range) 10.9 ± 10.1 (N = 151) 9.9 ± 10.9 (N = 36) 11.2 ± 9.8 (N = 114) NS
Anti-HTLV-1 titera
Serum (mean ± s.d., range) 29,141 ± 34,518
(N = 137)
28,067 ± 31,663
(N = 33)
29,482 ± 35,368
(N = 104)
NS
CSF (mean ± s.d., range) 594.2 ± 1180.2 (N = 133) 544.5 ± 1013.6 (N = 32) 609.9 ± 1227.8 (N = 101) NS
CSF tests
Cell count (/mm3) (mean ± s.d., range) 16.3 ± 27.6 (N = 144) 21.8 ± 48.3 (N = 36) 14.4 ± 15.0 (N = 108) NS
Protein (mg/dl) (mean ± s.d., range) 41.0 ± 17.9 (N = 145) 46.8 ± 19.9 (N = 36) 39.1 ± 16.8 (N = 109) 0.010
Neopterin (pmol/ml) (mean ± s.d., range) 33.5 ± 47.4 (N = 58) 34.1 ± 17.6 (N = 12) 33.3 ± 52.4 (N = 46) NS
HTLV-1 proviral load (copies/104 PBMC; mean ± s.d., range) 942.1 ± 1628.2 (N = 118) 1040.0 ± 1165.5
(N = 29)
910.2 ± 1751.6 (N = 89) NS
a Particle aggregation method. Data is shown as mean value ± s.d. (range), sample number.
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symptomswere markedly increased in patients with rapid progression.
3.3. Difference in clinical course between the sexes
We compared the clinical features of the female patients with those
ofmale patients to ﬁnd some association between the sexes and the dis-
ease courses. There is no signiﬁcant difference in OMDS and diseases
course between the sexes (Table 3). We tabulated frequencies of ﬁve
common symptoms including gait disturbance, urinary and sensory dis-
turbances, constipation and lumbago to ﬁnd a difference between the
sexes. There is no signiﬁcant difference in the initial symptom between
the sexes (Fig. 2b). Lastly, we calculated the ratio of rapid progression in
each decade of onset age. The proportion of patientswith rapid progres-
sion increased with the onset age both in male and female (Fig. 3a–c).
4. Discussion
Our result showed that the male to female ratio was 1:3 in 150 se-
quential patients with HAM/TSP. The prevalence in sex is almost as
same as that of previous studies. Approximately 25% of the patients in
our cohort manifested rapid disease progression and it is consistent
with previous studies showing 10–30% of all HAM/TSP patients follow
a disease course that progresses rapidly. Advanced age is shown to be
associated with rapid progression of the disease [14,16–18]. One may
think this phenomenon is attributed to the weakness of the lower ex-
tremities by aging or sex. However, the measured values of CSF cell
count, and protein levels were speciﬁcally elevated in patients with
rapid disease in the present study. Additionally, HTLV-1 antibody titerTable 2
Characteristics of the patients presenting with rapid and slow progression.
Type of diseases progression Rapid pr
Cases 39 (26%)
Female:Male 29:10 (7
Age (mean ± s.d.) 64.5 ± 8
Age of disease onset (mean ± s.d.) 61.5 ± 9
60.3 ± 1
65.1 ± 6
Duration of illness (mean ± s.d.) 2.9 ± 4.
Time between onset of disease to wheelchair use (mean ± s.d.) 1.4 ± 0.
Anti-HTLV-1 titera
Serum (mean ± s.d.) 29,965 ±
(N = 38
CSF (mean ± s.d.) 1210 ±
CSF tests
Cell count (/mm3) (mean ± s.d.) 11.1 ± 1
Protein (mg/dl) (mean ± s.d.) 54.9 ± 2
Neopterin (pmol/ml) (mean ± s.d.) 66.3 ± 8
HTLV-1 proviral load (copies/104 PBMC; mean ± s.d., range) 408 ± 3
a Particle aggregation method. Data is shown as mean value ± s.d. (range), sample numberin both serum and CSF were evaluated. Only in the CSF was a difference
detected between rapid and slowprogression. Althoughwe also expect-
ed the signiﬁcant elevation of neopterin, the difference did not reach
statistical signiﬁcance. It may be because of a small number of rapidly
progressing cases. In addition to small number of samples, we have to
take it into consideration the time point of the sample collection. The
blood samples were not always collected during progression of the dis-
ease. The rapid progression was deﬁned with the past history of the pa-
tient in this study.When the level of neopterin was elevated just during
the period of disease progression, the difference must be smaller than
we expected in our retrospective study. Together, these biomarkers sug-
gest inﬂammation, cellular and molecular events leading to spinal cord
tissue damage in HAM/TSP are indeed virus mediated. The high preva-
lence of rapid progression in older age is attributed to not only the
weakness of the legs by aging but also to some other factors.
A previous study on donated blood samples shows that therewas no
difference in prevalence of HTLV-1 carrier between the sexes until 5th
decades and that the prevalence in female become to be higher than
that inmale after 5th decades in Japan. [19]. The exact reason for the dif-
ference in prevalence is not elucidated. A sexual transmission may be
partially contributed to the difference. Concerned to blood transfusion,
the frequency of blood transfusion before the onset of the disease is sig-
niﬁcantly high comparedwith that in the general population [20]. HAM/
TSP sometimes occurs in the short period after blood transfusion. The
immune response of the host in an infection to HTLV-1 by blood trans-
fusion may be different from that in a mother-to-child infection by
breast feeding. Similarly, the immune response of the host to HTLV-1
in an infection by sexual intercourse in older age may be different
from that in a mother-to-child infection. So we hypothesized thatogression Slow progression
111 (74%)
4.4%:25.6%) 85:26 (76.6%:23.4%) NS
.4 60.3 ± 13.3 NS
.7 46.8 ± 15.7 b0.001
0.2 (female) 46.4 ± 16.3 (female) b0.001
.8 (male) 48.1 ± 15.7 (male) b0.001
4 13.5 ± 10.0 b0.001
8 (N = 14) 15.7 ± 11.6 (N = 29) b0.001
35,028
)
28,952 ± 34,465
(N = 98)
NS
1736 (N = 36) 366 ± 773 (N = 97) b0.001
5.6 (N = 38) 3.3 ± 3.5 (N = 105) b0.001
2.9 (N = 38) 36.1 ± 12.6 (N = 106) b0.001
4.9 (N = 8) 24.0 ± 20.2 (N = 45) NS
55 (N = 34) 1158 ± 1873 (N = 84) 0.008
.
a) Initial symptom of patients with rapid and slow 
    disease progression.
b) Initial symptom of male and female patients. 
Fig. 2. a. Initial symptom of patients with rapid and slow disease progression. b. Initial
symptom of male and female patients.
Fig. 3. Proportion of patients with rapid and slow disease progression by age of onset.
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mune response to HTLV-1, resulting in presenting with a rapid progres-
sion in elderly female. However, in the present study, we did not ﬁnd
out the difference in onset age, the ratio of rapid progression and the pe-
riod from onset to wheelchair-use between the sexes. Although we
think HTLV-1 can be transmitted by a sexual intercourse, one's gender
is not strongly associated with age of onset or diseases course of HAM/
TSP in the present study.
Biomarkers that are highly differential and may be of value in
supporting disease diagnosis which we identiﬁed in this retrospec-
tive study are CSF cells, protein level, and HTLV-1 antibody titer.Table 3
HAM/TSP clinical phenotypes and characteristics by gender.
Total (N =
Number of patients with rapid disease progression 39 (26%)
OMDS (mean, median, range) 5.2, 5, 0–1
Number of patients with disease severity above OMDS grade 5 47 (31.3%
Time between disease onset to wheelchair use (mean ± s.d., range) 9.8 ± 10.4
(N = 44)
Number of patients with familial history of HAM 8 (5.3%)HTLV-1 PVL in PBMC has been demonstrated to strongly correlate
with disease severity in a number of previous studies. And its utility
as a biomarker to aid in disease prognosis was also suggested by
Olindo et al. [16,18,21]. Unexpectedly, in our study, the patients
with rapid disease progression had lower PVL. Because the PVLs
were evaluated with the samples at their admission to our hospital,
the PBMCs are collected both from the patients before and during
rapid progression. We should warrant further investigations to ad-
dress the accepted hypothesis that disease progression and severity150) Male (N = 36) Female (N = 114) p
10 (27.8%) 26 (22.6%) NS
1 5.1, 5, 2–10 5.2, 5, 0–11 NS
) 11 (30.6%) 36 (31.6%) NS
13.8 ± 14
(N = 10)
8.7 ± 8.8
(N = 34)
NS
1 (2.8%) 7 (6.1%) NS
116 E. Matsuura et al. / Journal of the Neurological Sciences 371 (2016) 112–116are strictly driven by PVL in PBMC. The reasons for these differing ob-
servations are unclear at this point.
Our results suggest that age and virus mediated inﬂammation are
correlated with disease phenotypes while additional factors such as host
or HTLV-1 genetics and gender may inﬂuence disease susceptibility.
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